ClinicalTrials.gg
CompletedNCT03794180Updated Dec 18, 2019

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

A Phase 1 interventional study of TJ003234 and Placebo in Healthy Adult Subjects, sponsored by I-Mab Biopharma US Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-18.

Sponsored by I-Mab Biopharma US Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2019, 7 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

TJ003234RAR101 is a first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled, single ascending dose study of TJ003234 in healthy adults to determine whether TJ003234 is safe and tolerated when administered as an intravenous (IV) infusion and to determine the maximum dose tolerated (MTD).

02

Conditions studied

  • Healthy Adult Subjects

Keywords

  • Anti-GM-CSF agents
  • GM-CSF/GM-CSFR (GM-CSF receptor) antibody
  • colony-stimulating factor 2
  • monoclonal antibody
03

In context

Lead sponsor

I-Mab Biopharma US Limited is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand and willing to sign the form (ICF)
  • Healthy subjects 18-70 years of age
  • If of , agree to use protocol-specified
  • (BMI) 19.0-32.0 kg/m\^2
  • Blood pressure ≤ 139/89 mm Hg
  • Subjects are able to follow the study protocol and complete the trial

Exclusion criteria

Exclusion Criteria:

  • Current use of tobacco or nicotine-containing products or illicit drug use
  • History of severe allergic or anaphylactic reaction to a therapeutic drug or severe seasonal allergies
  • Any known pulmonary disease
  • Use of any prescription, drugs, herbal supplements, or nonprescription drugs within 1 month or 5 half-lives (whichever is longer) prior to study drug administration, or dietary supplements within 1 week prior to study drug administration, unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study
  • Abnormal hematological and chemistry laboratory values >10% above (ULN) or >10% below the lower limit of normal (LLN). (ANC) ≤ 1000 cells/mm\^3
  • Use of any biologic drugs in the last 120 days prior to dosing.
  • Immunization with a live or attenuated vaccine within 4 weeks prior to study drug administration
  • Prior treatment with any biologic anti-GM-CSF or GM-CSF receptor antagonists
  • ADA screening positive
  • Subjects who have a history of documented disease, even if not clinically severe or never treated with systemic or agents
  • A positive alcohol test and/or urine drug screen for substance of abuse at screening or upon check-in to the clinical site
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    TJ003234

    0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg via single IV infusion

    Drug: TJ003234

  • Placebo comparator
    Placebo

    0 mg/kg via single IV infusion

    Drug: Placebo

Interventions

  • Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline

  • DrugPlacebo

    Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline

06

What researchers measure

Primary outcomes

  1. Safety Profile: AEs

    Incidence of Adverse Events (AEs)

    Time frame: Up to 85 days after study drug administration

  2. Maximum Tolerated Dose

    Determine Maximum Tolerated Dose of TJ003234

    Time frame: Up to 85 days after study drug administration

Secondary outcomes

  1. Pharmacokinetic (PK) Parameters: Tmax

    Time of peak concentration (Tmax)

    Time frame: Up to 85 days after study drug administration

  2. Pharmacokinetic (PK) Parameters: Cmax

    Maximal Concentration (Cmax)

    Time frame: Up to 85 days after study drug administration

  3. Pharmacokinetic (PK) Parameters: T1/2

    Investigational product (IP) half-life (T1/2)

    Time frame: Up to 85 days after study drug administration

  4. Pharmacokinetic (PK) Parameters: CL

    Investigational Product (IP) Clearance (CL)

    Time frame: Up to 85 days after study drug administration

  5. Pharmacokinetic (PK) Parameters: AUC∞

    Area under the curve from time zero extrapolated to infinity (AUC∞)

    Time frame: Up to 85 days after study drug administration

  6. Anti-drug antibodies (ADA)

    Incidence and concentration of anti-drug antibodies

    Time frame: Up to 85 days after study drug administration

07

Study locations

1 site
  • Pharmaron
    Baltimore, Maryland 21201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Sep 2019, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2018
First posted
Jan 4, 2019
StartActual
Mar 18, 2019
Primary completionActual
Sep 5, 2019
CompletionActual
Sep 5, 2019
Last update
Dec 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03794180
Lead sponsor
I-Mab Biopharma US Limited
Responsible party
Sponsor
First posted
Jan 4, 2019
Start date
Mar 18, 2019
Primary completion
Sep 5, 2019
Completion
Sep 5, 2019
Last update
Dec 18, 2019

Study contacts

Claire Xu, MD, PhD
study director · I-Mab Biopharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plonmarlimab

Start the discussion